162 Timberwolf Pkwy Ste A2, Kalispell, MT 59901Mon–Thu 9–4
CareCredit FinancingFacebookInstagram
alpine health and wellness main logo
SERVICES
TREATMENTS
HORMONE OPTIMIZATION
GLP-1 WEIGHT MANAGEMENT THERAPY
Peptide therapy
KETAMINE INFUSION THERAPY
IV NUTRITIONAL THERAPY
NAD+
Aesthetic services
Laser skin rejuvenation
Body contouring
EMSELLA pelvic floor strengthening
Functional Wellness Labs
Weight LossPeptidesHormones
ketamine therapy
ABOUT US
BLOG
CONTACT US
406-361-7421BOOK APPOINTMENT
Reclining infusion chair with IV pole and mountain view in a Kalispell, MT clinic used for monitored ketamine infusions

IV Ketamine vs Spravato vs At-Home Ketamine: Cost, Insurance, Safety and Which Fits You

IV ketamine, Spravato and at-home ketamine are three different ways to use the same family of medicines for depression, and they differ most in FDA status, insurance coverage and how closely you are monitored. Spravato (esketamine nasal spray) is FDA-approved for treatment-resistant depression and is covered by Medicare Part B and many commercial plans, which usually require prior authorization. [1][25][26] IV ketamine is used off-label and is usually self-pay, and comparison studies, mostly observational, suggest it works about as well. [4][14][28] At-home compounded ketamine has the least oversight, and the FDA has warned about it. [5] At Alpine Health & Wellness in Kalispell, MT, we provide monitored IV ketamine infusions by referral.

The short answer

  • Spravato is FDA-approved for adults with treatment-resistant depression, given only in certified clinics with at least 2 hours of monitoring after every dose. [1]
  • IV ketamine is FDA-approved only as an anesthetic, so using it for depression is off-label. [4] It has been studied in randomized trials for depression since 2000, with a larger NIMH trial in 2006. [32][29]
  • No randomized trial has compared IV ketamine directly with Spravato nasal spray. The best available comparisons, mostly observational, show similar response rates, with IV ketamine possibly working faster. [14]
  • Cost: Spravato is covered by Medicare Part B and many commercial plans, usually after prior authorization. [25][26] IV ketamine is usually self-pay; in one 2026 directory analysis, the median posted price was $400 per infusion. [28]
  • At-home compounded ketamine is not FDA-approved for any psychiatric use, and the FDA warns that home use lacks onsite monitoring. [5]

How do IV ketamine, Spravato and at-home ketamine compare?

IV ketamine infusionSpravato (esketamine nasal spray)At-home compounded ketamine (lozenges, tablets, sprays)
FDA status for depressionOff-label; FDA-approved only for anesthesia [4]FDA-approved for treatment-resistant depression (2019) and for depression with acute suicidal thoughts; approved as monotherapy in January 2025 [1][2][3]Not FDA-approved for any psychiatric disorder [5]
Where it's givenMedical office, by IV, usually over about 40 minutes in studies [8][10]Only in REMS-certified healthcare settings; you spray it yourself under supervision and can't take it home [1][2]At home
MonitoringExperts advise monitoring heart, blood pressure, breathing and oxygen, and suggest considering up to 2 hours; the ideal length is unknown [19]At least 2 hours after each dose, including pulse oximetry [1]No provider onsite [5]
DosingAdjusted to body weight, commonly 0.5 mg/kg [8][10]Fixed doses of 56 mg or 84 mg [1]Varies by prescriber and compounder; FDA says no safe dosing has been established for psychiatric use [5]
Typical scheduleOften 6 infusions over about 2 to 3 weeks in studies [7][9][10]Twice weekly for weeks 1 to 4, weekly for weeks 5 to 8, then weekly or every 2 weeks [1]Varies
InsuranceUsually self-pay [28]Covered by Medicare Part B and many commercial plans with prior authorization [25][26]Varies; not FDA-approved for any psychiatric use [5]

Does IV ketamine or Spravato work better?

There is no clear winner, because the two have never been tested against each other in a randomized trial. The only randomized head-to-head trial compared IV ketamine with IV esketamine, not the nasal spray, and found them similar. [30] Here is what the rest of the evidence shows.

StudyWhat it comparedPeopleKey result
Murrough 2013 [6]Single IV ketamine infusion vs midazolam (active placebo)73Response at 24 hours: 64% vs 28%
ELEKT-D, Anand 2023 [10]IV ketamine vs electroconvulsive therapy (ECT), not industry funded403Response: 55.4% vs 41.2%; ketamine was noninferior (at least as good) to ECT
TRANSFORM-2, Popova 2019 [11]Spravato plus new antidepressant vs placebo spray plus new antidepressant (Janssen funded)227Depression scores improved about 4 points more with Spravato at day 28
ESCAPE-TRD, Reif 2023 [12]Spravato vs quetiapine, both with an antidepressant (Janssen funded)676Remission at week 8: 27.1% vs 17.6%
Bahji 2021 meta-analysis [13]IV ketamine trials vs esketamine trials, compared indirectly1,877 in 24 trialsIV ketamine showed larger response and remission effects, but trial designs differed
Elmosalamy 2025 meta-analysis [14]Studies that compared IV ketamine and esketamine head to head, mostly observational978 in 8 studiesSimilar response and remission; IV ketamine may act faster

Two honest caveats. The FDA noted that only one of Spravato's three short-term trials met its main goal. [2] And the IV ketamine evidence comes from smaller trials. [13] In a Mayo Clinic comparison of 62 patients, response rates were similar, but people on IV ketamine reached remission faster. [15]

How long do the effects last?

Ketamine's effect is often fast but short-lived without repeat treatment. [17]

  • After a single infusion in an early trial, 35% of patients still met response criteria at 1 week. [29]
  • After a series of 6 infusions, 8 of 9 patients in one small study relapsed, on average 19 days later. [7]
  • In a 2019 trial, 59% responded after a series of infusions, typically after about 3 infusions, and weekly maintenance infusions held the gains during the maintenance phase. [9]
  • For Spravato, the label's relapse-prevention trial found fewer relapses when patients kept using it, and most people in stable remission were dosed every other week. [1]

An American Psychiatric Association task force has also cautioned that long-term data on ketamine's effectiveness and safety are limited. [18]

The practical point: whichever option you choose, ask about the plan after the first few weeks, because maintenance treatment is common for both.

What does each option cost?

Spravato and IV ketamine are paid for in very different ways.

  • Spravato: Commercial plans usually require prior authorization. Cigna's 2026 policy, for example, requires that you have not responded to at least two antidepressants from different drug classes, each taken for at least 6 weeks. [26] Medicare pays for Spravato sessions under its physician fee schedule. [25] The manufacturer's savings program says commercially insured patients may pay "as little as $10 per treatment" for the medicine, but Medicare, Medicaid, TRICARE and VA patients can't use it, and it does not cover the observation time. [27]
  • IV ketamine: Usually self-pay. A July 2026 directory analysis of 91 clinics that post prices found a median of $400 per infusion, with the middle half of posted prices between $375 and $475; about 9 in 10 clinics don't post prices at all. [28]
  • Health-system cost: A 2026 VA study found an 8-treatment course cost the VA $6,069 for Spravato vs $647 for intramuscular ketamine, mostly because of the drug price. [16] That is what the VA paid, not what a patient pays.

At Alpine Health & Wellness, IV ketamine is self-pay. Insurance does not cover our infusions, but you can use an HSA or FSA, and CareCredit financing is available. Call us for current pricing.

Is at-home ketamine safe?

At-home ketamine raises the most safety questions. In October 2023, the FDA warned patients and providers about compounded ketamine for psychiatric use. Its main points: [5]

  • "Ketamine is not FDA approved for the treatment of any psychiatric disorder."
  • At-home use "presents additional risks because a health care provider is not available onsite to monitor" for sedation and dissociation.
  • In 2023, the FDA received a report of a patient whose breathing slowed after taking compounded oral ketamine at home for PTSD, with a blood level about twice what is typical for anesthesia.
  • The FDA said it is not aware of evidence that compounded ketamine is safer, more effective or faster than FDA-approved treatments.

Telehealth programs differ in how they screen and follow patients, so ask any provider how they would handle a bad reaction at home.

What are the side effects and risks?

Both drugs cause the same kinds of side effects, usually during or shortly after a dose. The two columns below come from different kinds of studies, so they are not a head-to-head comparison.

Side effectSpravato vs placebo, from the label [1]IV ketamine, community clinic data (203 patients) [23]
Dissociation (feeling detached or "floaty")41% vs 9%35.6%
Dizziness29% vs 8%45.2%
Nausea28% vs 9%13.3%
Sedation or drowsiness23% vs 9%56.4%
Blood pressure increase10% vs 3%44.3% met criteria for a treatment-related high reading

Other risks to know about:

  • Blood pressure rises during treatment and usually settles within a few hours. [1][19] Experts advise against ketamine for people with uncontrolled high blood pressure, aneurysm disease, or a heart attack within the past 6 weeks. [19]
  • Psychosis history: Ketamine can briefly cause psychotic-like symptoms, and experts urge caution in people with a history of psychosis. [19]
  • Bipolar depression: A 2026 trial in 68 people with bipolar depression who were taking a mood stabilizer or antipsychotic found no cases of mania during the study. [21] A review estimated a mood-switch rate of about 2.4%. [22] At least one insurer's 2026 policy lists bipolar depression as an investigational use of Spravato. [31]
  • Bladder problems: Severe bladder and kidney problems are well documented in people who misuse ketamine heavily and often. [24] The Spravato label notes no such cases in its studies of up to a year. [1]
  • Pregnancy: The Spravato label warns it may cause fetal harm and advises against breastfeeding. [1]

Which option fits you? A decision guide

Use this to prepare questions for your provider, not to choose on your own.

  • You have commercial insurance or Medicare and have tried at least two antidepressants: Spravato may cost you less, because it is FDA-approved and covered by many plans. [25][26][27]
  • You are paying out of pocket, or Spravato wasn't covered or didn't help: IV ketamine may be worth discussing. It allows weight-based dosing and, in comparison studies, may work faster. [14][15]
  • You are considering at-home ketamine: Read the FDA's warning first and ask how you will be monitored. [5]
  • You have uncontrolled blood pressure, a history of psychosis, are pregnant, or have an active substance use problem: Talk with your doctor before considering any form of ketamine. [1][19]
  • You haven't tried standard treatment yet: The VA/DoD guideline suggests against ketamine or esketamine as a first medication and supports them as an add-on after several medications haven't worked. [20]

IV ketamine infusions at Alpine Health & Wellness in Kalispell

Here is what IV ketamine looks like at our clinic on Timberwolf Parkway in Kalispell:

  1. Referral: You need a referral from your primary care or mental health provider.
  2. The infusion: You relax in a reclining chair for 45 minutes to an hour. A registered nurse anesthetist or licensed nurse practitioner monitors you continuously. You stay awake, though you may feel mild to moderate sedation or unusual sensations, such as changes in how light and color look.
  3. Recovery: We monitor you for 30 to 45 minutes after the infusion ends.
  4. The series: At least 2 to 3 infusions are usually needed to see whether ketamine helps you. If it does, a series of up to 6 infusions over 2 weeks is typical, followed by a maintenance plan if appropriate.

Ketamine care comes up regularly in our Google reviews, and patients often mention feeling cared for by a knowledgeable team. We see patients from Kalispell, Whitefish, Columbia Falls, Bigfork and across the Flathead Valley. Learn more in our guide to ketamine infusion therapy for depression.

Frequently asked questions

Is ketamine therapy FDA-approved?

Partly. Spravato, a nasal spray form called esketamine, is FDA-approved for treatment-resistant depression. [1] Ketamine itself is FDA-approved only as an anesthetic, so IV ketamine for depression is off-label. [4]

Is Spravato the same as ketamine?

Not exactly. Standard ketamine is a 50/50 mix of two mirror-image forms of the same molecule, and esketamine is one of them. Spravato is a fixed-dose nasal spray of esketamine, while IV ketamine contains both forms and is dosed by body weight. [1]

Is ketamine therapy covered by insurance?

Spravato is covered by Medicare Part B and many commercial plans, usually with prior authorization. [25][26] IV ketamine for depression usually is not, so most patients pay out of pocket. [28] At Alpine, our infusions are self-pay, and HSA, FSA and CareCredit are accepted.

Does ketamine therapy get you high?

It can cause temporary dissociation, a detached or dreamlike feeling. In the Spravato trials, 41% of patients reported dissociation, which happened on the day of dosing and passed. [1] That is one reason both treatments are monitored in a clinic.

How long does IV ketamine last for depression?

It varies. After one infusion, effects often fade within about a week. [29] After a series, relapse can occur within weeks without maintenance. [7] Many people need maintenance treatment.

Talk with us about IV ketamine infusions in Kalispell

Call Alpine Health & Wellness in Kalispell, MT at 406-361-7421 or book a consultation online. A referral from your primary care or mental health provider is required. Learn more about our ketamine infusion therapy.

If you are in crisis or thinking about suicide, call or text 988 to reach the 988 Suicide & Crisis Lifeline, or call 911.

Sources

  1. Janssen. Spravato (esketamine) nasal spray prescribing information, revised March 2026. DailyMed. https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=d81a6a79-a74a-44b7-822c-0dfa3036eaed&type=display
  2. U.S. FDA. FDA approves new nasal spray medication for treatment-resistant depression. March 5, 2019. http://web.archive.org/web/20250515053054/https://www.fda.gov/news-events/press-announcements/fda-approves-new-nasal-spray-medication-treatment-resistant-depression-available-only-certified
  3. Johnson & Johnson. Spravato approved in the U.S. as the first and only monotherapy for adults with treatment-resistant depression. January 21, 2025. https://www.jnj.com/media-center/press-releases/spravato-esketamine-approved-in-the-u-s-as-the-first-and-only-monotherapy-for-adults-with-treatment-resistant-depression
  4. Par Health. Ketalar (ketamine hydrochloride) injection prescribing information. DailyMed. https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=14e8f864-8b8a-4e7e-8439-e510d3107063&type=display
  5. U.S. FDA. FDA warns patients and health care providers about potential risks associated with compounded ketamine products. October 10, 2023 (archived copy). http://web.archive.org/web/20260530025451/https://www.fda.gov/drugs/human-drug-compounding/fda-warns-patients-and-health-care-providers-about-potential-risks-associated-compounded-ketamine
  6. Murrough JW, et al. Antidepressant efficacy of ketamine in treatment-resistant major depression. Am J Psychiatry. 2013;170(10):1134-1142. https://pubmed.ncbi.nlm.nih.gov/23982301/
  7. aan het Rot M, et al. Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression. Biol Psychiatry. 2010;67(2):139-145. https://pubmed.ncbi.nlm.nih.gov/19897179/
  8. Singh JB, et al. A double-blind, randomized, placebo-controlled, dose-frequency study of intravenous ketamine. Am J Psychiatry. 2016;173(8):816-826. https://pubmed.ncbi.nlm.nih.gov/27056608/
  9. Phillips JL, et al. Single, repeated, and maintenance ketamine infusions for treatment-resistant depression. Am J Psychiatry. 2019;176(5):401-409. https://pubmed.ncbi.nlm.nih.gov/30922101/
  10. Anand A, et al. Ketamine versus ECT for nonpsychotic treatment-resistant major depression. N Engl J Med. 2023;388(25):2315-2325. https://pubmed.ncbi.nlm.nih.gov/37224232/
  11. Popova V, et al. Efficacy and safety of flexibly dosed esketamine nasal spray (TRANSFORM-2). Am J Psychiatry. 2019;176(6):428-438. https://pubmed.ncbi.nlm.nih.gov/31109201/
  12. Reif A, et al. Esketamine nasal spray versus quetiapine for treatment-resistant depression. N Engl J Med. 2023;389(14):1298-1309. https://pubmed.ncbi.nlm.nih.gov/37792613/
  13. Bahji A, Vazquez GH, Zarate CA Jr. Comparative efficacy of racemic ketamine and esketamine for depression. J Affect Disord. 2021;278:542-555. https://pubmed.ncbi.nlm.nih.gov/33022440/
  14. Elmosalamy A, et al. Intravenous ketamine versus esketamine for depression: systematic review and meta-analysis. Ther Adv Psychopharmacol. 2025;15. https://pubmed.ncbi.nlm.nih.gov/41244961/
  15. Singh B, et al. Comparative effectiveness of intravenous ketamine and intranasal esketamine in clinical practice. J Clin Psychiatry. 2023;84(2). https://pubmed.ncbi.nlm.nih.gov/36724113/
  16. Bhatt KV, et al. Real-world effectiveness and cost-differential of intranasal esketamine versus intramuscular ketamine. Psychiatr Res Clin Pract. 2026;8(3):112-119. https://pubmed.ncbi.nlm.nih.gov/42500270/
  17. Smith-Apeldoorn SY, et al. Maintenance ketamine treatment for depression: a systematic review. Lancet Psychiatry. 2022;9(11):907-921. https://pubmed.ncbi.nlm.nih.gov/36244360/
  18. Sanacora G, et al. A consensus statement on the use of ketamine in the treatment of mood disorders. JAMA Psychiatry. 2017;74(4):399-405. https://pubmed.ncbi.nlm.nih.gov/28249076/
  19. McIntyre RS, et al. Synthesizing the evidence for ketamine and esketamine in treatment-resistant depression: an international expert opinion. Am J Psychiatry. 2021;178(5):383-399. https://pubmed.ncbi.nlm.nih.gov/33726522/
  20. U.S. Department of Veterans Affairs and Department of Defense. Clinical Practice Guideline for the Management of Major Depressive Disorder. 2022. https://www.healthquality.va.gov/guidelines/MH/mdd/VADODMDDCPGFinal508.pdf
  21. Orsini DK, et al. Serial ketamine infusions for treatment-resistant bipolar depression: a randomized clinical trial. JAMA Psychiatry. 2026. https://pubmed.ncbi.nlm.nih.gov/42684694/
  22. Nunez NA, et al. Single and serial intravenous ketamine and esketamine for bipolar depression: systematic review and meta-analysis. Brain Sci. 2023;13(12):1672. https://pubmed.ncbi.nlm.nih.gov/38137120/
  23. Rodrigues NB, et al. Safety and tolerability of IV ketamine in adults with major depressive or bipolar disorder. Expert Opin Drug Saf. 2020;19(8):1031-1040. https://pubmed.ncbi.nlm.nih.gov/32539491/
  24. Chan EOT, et al. Systematic review and meta-analysis of ketamine-associated uropathy. Hong Kong Med J. 2022;28(6):466-474. https://pubmed.ncbi.nlm.nih.gov/36464318/
  25. Centers for Medicare & Medicaid Services. CY 2020 Physician Fee Schedule Final Rule (esketamine codes G2082 and G2083). Federal Register. November 15, 2019. https://www.federalregister.gov/documents/full_text/text/2019/11/15/2019-24086.txt
  26. Cigna. Psychiatry: Spravato Prior Authorization Policy. 2026. https://a.static.cigna.com/assets/chcp/pdf/coveragePolicies/cnf/cnf_606_coveragepositioncriteria_psychiatry_spravato_pa.pdf
  27. Janssen. SPRAVATO withMe Savings Program requirements. https://www.spravato.com/files/spravatowithmeprogramrequirements.pdf
  28. HealingMaps. What a ketamine infusion costs in 2026: every posted price in our directory, analyzed. 2026 (directory data, not peer reviewed). https://healingmaps.com/ketamine-infusion-cost-2026-directory-analysis/
  29. Zarate CA Jr, et al. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry. 2006;63(8):856-864. https://pubmed.ncbi.nlm.nih.gov/16894061/
  30. Correia-Melo FS, et al. Efficacy and safety of adjunctive therapy using esketamine or racemic ketamine for adult treatment-resistant depression. J Affect Disord. 2020;264:527-534. https://pubmed.ncbi.nlm.nih.gov/31786030/
  31. Premera Blue Cross. Medical Policy 5.01.609: Spravato (esketamine) nasal spray. Effective June 1, 2026. https://www.premera.com/medicalpolicies-individual/5.01.609.pdf
  32. Berman RM, et al. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry. 2000;47(4):351-354. https://pubmed.ncbi.nlm.nih.gov/10686270/

This article is for general information only and is not medical advice. Compounded medications are not FDA-approved, and the FDA does not verify the safety, effectiveness, or quality of compounded drugs before they are marketed. No specific outcome is promised or implied. Whether any therapy is appropriate for you can only be determined by a licensed provider after an evaluation.

Quick Links

Hormone Optimization
Peptide Therapy
Aesthetic Services
InjectablesLaser Skin RejuvenationAlma OPUS Skin Rejuvenation
Call Us: (406) 361-7421
BOOK AN APPOINTMENT
Our Location
‍
162 Timberwolf Parkway Suite A2,
Kalispell, MT 59901

Call us
406-361-7421
FAX
406-201-3233
Important Links
Body Sculpting
EMSELLA
INJECTABLES
IV NUTRITIONAL THERAPY
HORMONE OPTIMIZATION
NAD+
KETAMINE INFUSION THERAPY
semaglutide for weight loss
opus plasma skin rejuvenation
Follow us
© 2023 Alpine Health & Wellness | Terms & Conditions | Privacy Policy‍
Powered by PatientQ